Measuring and evaluating interferon beta-induced antibodies in patients with multiple sclerosis

C Ross; K M Clemmesen; P S Sørensen; Nils Koch-Henriksen; K Bendtzen

Measuring and evaluating interferon beta-induced antibodies in patients with multiple sclerosis

C Ross, K M Clemmesen, P S Sørensen, Nils Koch-Henriksen, K Bendtzen

Department of Clinical Medicine

32 Citations (Scopus)

Abstract

Administration of interferons (IFNs) may induce antibodies that interfere with therapeutic efficacy. We have optimized and validated methods for large-scale economic screening. Sera from patients with relapsing-remitting multiple sclerosis (MS) were investigated for binding antibody (BAb) by protein-G affinity-chromatography radioimmunoassay and a commercially available enzyme immunoassay (EIA). Neutralizing antibody (NAb) was investigated by cytopathic effect assays (CEA) using both fixed amount and serially diluted sera. BAb correlated with log10-transformed titres obtained by EIA (r=0.70, P

Original language	English
Journal	Multiple Sclerosis
Volume	12
Issue number	1
Pages (from-to)	39-46
Number of pages	8
ISSN	1352-4585
Publication status	Published - 1 Feb 2006

Cite this

@article{b282303d7fd14ebfa320ec8322d8ed97,

title = "Measuring and evaluating interferon beta-induced antibodies in patients with multiple sclerosis",

abstract = "Administration of interferons (IFNs) may induce antibodies that interfere with therapeutic efficacy. We have optimized and validated methods for large-scale economic screening. Sera from patients with relapsing-remitting multiple sclerosis (MS) were investigated for binding antibody (BAb) by protein-G affinity-chromatography radioimmunoassay and a commercially available enzyme immunoassay (EIA). Neutralizing antibody (NAb) was investigated by cytopathic effect assays (CEA) using both fixed amount and serially diluted sera. BAb correlated with log10-transformed titres obtained by EIA (r=0.70, P",

author = "C Ross and Clemmesen, {K M} and S{\o}rensen, {P S} and Nils Koch-Henriksen and K Bendtzen",

year = "2006",

month = feb,

day = "1",

language = "English",

volume = "12",

pages = "39--46",

journal = "Multiple Sclerosis",

issn = "1352-4585",

publisher = "SAGE Publications",

number = "1",

}

TY - JOUR

T1 - Measuring and evaluating interferon beta-induced antibodies in patients with multiple sclerosis

AU - Ross, C

AU - Clemmesen, K M

AU - Sørensen, P S

AU - Koch-Henriksen, Nils

AU - Bendtzen, K

PY - 2006/2/1

Y1 - 2006/2/1

N2 - Administration of interferons (IFNs) may induce antibodies that interfere with therapeutic efficacy. We have optimized and validated methods for large-scale economic screening. Sera from patients with relapsing-remitting multiple sclerosis (MS) were investigated for binding antibody (BAb) by protein-G affinity-chromatography radioimmunoassay and a commercially available enzyme immunoassay (EIA). Neutralizing antibody (NAb) was investigated by cytopathic effect assays (CEA) using both fixed amount and serially diluted sera. BAb correlated with log10-transformed titres obtained by EIA (r=0.70, P

AB - Administration of interferons (IFNs) may induce antibodies that interfere with therapeutic efficacy. We have optimized and validated methods for large-scale economic screening. Sera from patients with relapsing-remitting multiple sclerosis (MS) were investigated for binding antibody (BAb) by protein-G affinity-chromatography radioimmunoassay and a commercially available enzyme immunoassay (EIA). Neutralizing antibody (NAb) was investigated by cytopathic effect assays (CEA) using both fixed amount and serially diluted sera. BAb correlated with log10-transformed titres obtained by EIA (r=0.70, P

M3 - Journal article

SN - 1352-4585

VL - 12

SP - 39

EP - 46

JO - Multiple Sclerosis

JF - Multiple Sclerosis

IS - 1

ER -

Measuring and evaluating interferon beta-induced antibodies in patients with multiple sclerosis

Abstract

Fingerprint

Cite this